UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008068
Receipt number R000009504
Scientific Title Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis in patients with diabetes and liver dysfunction
Date of disclosure of the study information 2012/06/01
Last modified on 2013/12/03 15:49:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis in patients with diabetes and liver dysfunction

Acronym

Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis

Scientific Title

Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis in patients with diabetes and liver dysfunction

Scientific Title:Acronym

Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis

Region

Japan


Condition

Condition

Diabetes Mellitus
Liver dysfunction
Hypertension

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the degree of hepatic fibrosis, presence of NASH in patients with type 2 diabetes, and to examine the inhibitory effects on hepatic fibrosis with DPP-4 inhibitors(and ARB).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Suppression of hepatic fibrosis
(Markers of fibrosis, such as hyaluronic acid, type IV collagen7S, and P3P. The degree of liver fibrosis by liver biopsy)

Key secondary outcomes

Improvement of liver function
(TP, Alb, ChE, AST, ALT, LDH, ALP, r-GTP, T-Bil)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients over 20 years old
2) type 2 diabetes and ALT> 30

Key exclusion criteria

1) Patients with co-infection with hepatitis B virus
2) Patients with co-infection with hepatitis C virus
3) Patients with autoimmune hepatitis, primary biliary cirrhosis
4) Patients with alcohol addict (more than 20g/day)
5) Patients with insulin therapy

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hitoshi Yoshiji

Organization

Nara Medical University

Division name

Third department of Internal Medicine

Zip code


Address

Shijyo-cho 840, Kashihara, Nara, Japan

TEL

0744-22-3051

Email

3naika@naramed-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryuichi Noguchi

Organization

Nara Medical University

Division name

Third department of Internal Medicine

Zip code


Address

Shijyo-cho 840, Kashihara, Nara, Japan

TEL

0744-22-3051

Homepage URL


Email

3naika@naramed-u.ac.jp


Sponsor or person

Institute

Third department of Internal Medicine, Nara Medical University

Institute

Department

Personal name



Funding Source

Organization

Third department of Internal Medicine, Nara Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

奈良県立医科大学附属病院(奈良県)
県立奈良病院(奈良県)
独立行政法人国立病院機構 奈良医療センター(奈良県)
県立五條病院(奈良県)
国保中央病院(奈良県)
県立三室病院(奈良県)
大和高田市立病院(奈良県)
高の原中央病院(奈良県)
西奈良中央病院(奈良県)
大倭病院(奈良県)
高宮病院(奈良県)
服部記念病院(奈良県)
平成記念病院(奈良県)
済生会御所病院(奈良県)
豊川総合病院(大阪府)
ベルランド総合病院(大阪府)
医真会八尾総合病院(大阪府)
福島県立医大 消化器内科(福島県)
公立藤田総合病院(福島県)
福島赤十字病院(福島県)
塙厚生病院(福島県)
大牟田市立病院(福岡県)


Other administrative information

Date of disclosure of the study information

2012 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 05 Month 10 Day

Date of IRB


Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date

2015 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Factors to consider the relevance and results


Management information

Registered date

2012 Year 05 Month 31 Day

Last modified on

2013 Year 12 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009504


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name